Cocoa-carob blend acute intake modifies miRNAs related to insulin sensitivity in type 2 diabetic subjects: a randomised controlled nutritional trial

• Published in: Food & function Vol. 16; no. 8; pp. 3211 - 3226
• Main Authors: Villalva, Marisol, García-Díez, Esther, López de las Hazas, María del Carmen, Lo Iacono, Oreste, Vicente-Díez, José Ignacio, García-Cabrera, Sara, Alonso-Bernáldez, Marta, Dávalos, Alberto, Martín, María Ángeles, Ramos, Sonia, Pérez-Jiménez, Jara
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 14.04.2025
• Subjects: Adult; Aged; Blood Glucose - metabolism; Body weight; Cacao - chemistry; Cacao - metabolism; Carob; Cocoa; Cross-Over Studies; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - diet therapy; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - metabolism; Dietary fiber; Female; Galactans - administration & dosage; Galactans - metabolism; Glucagon-Like Peptide 1 - blood; Glucagon-Like Peptide 1 - metabolism; Glucose; Homeostasis; Humans; Hunger; Insulin; Insulin - blood; Insulin - metabolism; Insulin Resistance; Male; Mannans; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; Middle Aged; miRNA; Overweight; Parameter modification; Plant Gums - administration & dosage; Plant Gums - metabolism; Polyphenols; Population studies; Postprandial Period; Satiety; Sensitivity
• ISSN: 2042-6496; 2042-650X; 2042-650X
• DOI: 10.1039/d4fo04498c

Postprandial metabolic disturbances are exacerbated in type 2 diabetes (T2D). Cocoa and carob, despite showing promising effects on these alterations in preclinical studies, have not yet been jointly tested in a clinical trial. Therefore, this acute, randomised, controlled, crossover nutritional trial evaluated the postprandial effects of a cocoa-carob blend (CCB) in participants with T2D ( n = 20) and overweight/obesity. The subjects followed three treatments: hypercaloric breakfast (high-sugar and high-saturated fat, 900 kcal) as the control (treatment C); the same breakfast together with 10 g of the CCB, with 5.6 g of dietary fibre and 1.6 g of total polyphenols (treatment A); and the same breakfast after consuming the CCB (10 g) the night before (treatment B). Various analyses were performed, including the determination of the clinical markers of T2D (fasting and postprandial glucose and insulin, GLP-1, and glycaemic profile), satiety evaluation, analysis of exosomal miRNA expression and ex vivo determination of inflammation modulation. No effect on glucose homeostasis (glucose, insulin, and GLP-1) was found in the study population. However, eight exosomal miRNAs were found to be significantly modified owing to CCB supplementation compared with treatment C, with three of them (miR-20A-5p, miR-23A-3p, and miR-17-5p) associated with an improvement in insulin sensitivity. Furthermore, the CCB caused a decrease in hunger feelings (0-120 min), as assessed by the visual analogue scale (VAS). Finally, treatment A caused a significant decrease in the glucose increment within 0-30 min of treatment in subjects with overweight. No significant modifications were found in the other assessed parameters. The acute intake of the CCB by subjects with T2D showed modest although significant results, which need to be validated in a long-term randomised controlled trial. Postprandial metabolic disturbances are exacerbated in type 2 diabetes (T2D).